Cambridge Heart Presents At Adams, Harkness & Hill Symposium.

Business Editors & Health/Medical Writers

BEDFORD, Mass.--(BW HealthWire)--Aug. 7, 2002

David A. Chazanovitz Discusses Role of Microvolt T-Wave Alternans 

in Treatment of Individuals at Risk of Sudden Cardiac Death 

Cambridge Heart, Inc. (NASDAQ-CAMH) today announced that David A. Chazanovitz, President and CEO spoke on the relevance of Microvolt T-Wave Alternans (MTWA) in aiding the identification of individuals at risk of Sudden Cardiac Death by use of the non-invasive MTWA Test at the "New Frontiers in the Treatment of Cardiac Disease" symposium sponsored by Adams, Harkness & Hill. The symposium, held in Boston, MA on August 5, 2002, was designed to consolidate scientific technology and investment information as an aid to discriminate among opportunities in the current environment.

Mr. Chazanovitz reviewed the results of multiple clinical studies supporting the effectiveness of the MTWA Test in patient populations with varying types of cardiac disease, including MADIT II type patients, post myocardial infarction patients, heart failure patients, and syncope patients at the meeting.

During his presentation Mr. Chazanovitz stated that, "Microvolt T-Wave Alternans allows the practicing cardiologist to find more of the right patients that could benefit from Implantable Cardioverter Defibrillator (ICD) therapy, while also successfully establishing which patients are at minimal risk of suffering a Sudden Cardiac Arrest."

Mr. Chazanovitz went on to say, "Clinical use of MTWA in various cardiology practices demonstrates that approximately 1 in 5 MTWA Tests performed in patient populations often not referred to invasive electrophysiology study, leads to the placement of an ICD. MTWA enables the use of this potentially life saving therapy in individuals at risk, many of whom often go undetected."

Sudden Cardiac Death strikes approximately 400,000 individuals in the US every year. The Microvolt T-Wave Alternans Test was developed to identify these individuals before it is too late.

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heartrate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1992, is based in Bedford, Massachusetts and is traded on the NASDAQ/NMS under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

Statements contained in this press release about obtaining third-party reimbursement four use of our products, anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.